Studies shorter:longer | Shorter events/total | Longer events/total | Propensity score matched multivariable meta-regression | |||
Pairs | aOR (95% CI) | aRD (95% CI) | ||||
Failure or relapse versus success | 9:10 | 81/881 | 10/135 | 135 | 1.4 (0.5–4.1) | 0.03 (−0.05–0.11) |
Death during first 12 months of treatment versus success | 9:9 | 79/879 | 13/138 | 138 | 2.5 (1.0–6.3)+ | 0.11 (−0.01–0.22) |
Lost versus success, failure or relapse | 9:10 | 44/925 | 14/149 | 149 | 0.6 (0.1–4.5) | −0.01 (−0.09–0.07) |
Data are presented as n, unless otherwise stated. aOR: adjusted odds ratio; aRD: adjusted risk difference. All models adjusted for age, sex, HIV status, previous treatment with first-line TB medications and extensiveness of disease. Results were adjusted as described in the Methods. +: confidence intervals suggestive of increased odds or risk of death with the shorter regimen.